Novavax is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. Novavax's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza and the Ebola virus.

Type
Public
HQ
Gaithersburg, US
Founded
1987
Size (employees)
355 (est)
Novavax was founded in 1987 and is headquartered in Gaithersburg, US
Report incorrect company information

Novavax Office Locations

Novavax has an office in Gaithersburg, Rockville and Uppsala
Gaithersburg, US (HQ)
20 Firstfield Rd
Rockville, US
9920 Belward Campus Dr
Uppsala, SE
109 Kungsgatan
Show all (3)
Report incorrect company information

Novavax Financials and Metrics

Novavax Financials

Novavax's revenue was reported to be $15.35 m in FY, 2016 which is a 57.6% decrease from the previous period.
USD

Revenue (Q2, 2017)

6.7 m

Net income (Q2, 2017)

(44.5 m)

EBIT (Q2, 2017)

(41.5 m)

Market capitalization (5-Feb-2018)

693.7 m

Cash (4-Feb-2018)

75.8 m

EV

934.9 m
Novavax's current market capitalization is $693.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

20.9 m30.7 m36.3 m15.4 m

Revenue growth, %

(5%)47%18%(58%)

General and administrative expense

14.8 m19.9 m30.8 m46.5 m

R&D expense

50.3 m79.4 m162.6 m237.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

4.8 m7.5 m8.3 m8.2 m9.9 m14 m6.5 m4.2 m2.5 m3.2 m5.7 m6.7 m

General and administrative expense

3.9 m4.3 m5.8 m4.8 m5.8 m7.1 m9.1 m10.5 m14.1 m13.6 m8.9 m8.9 m

R&D expense

13.9 m14.5 m15.2 m19.2 m25.9 m25 m27.9 m69 m64.9 m53 m37.7 m39.3 m

Operating expense total

20.1 m21.8 m26.1 m28 m34.2 m34.8 m39.7 m79.5 m79 m66.5 m46.5 m48.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

119.5 m32.3 m93.1 m144.4 m

Accounts Receivable

1.9 m7.5 m2.3 m233 k

Inventories

9.2 m19.3 m21.8 m

Current Assets

145 m188.2 m287.3 m287.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

122.5 m109.9 m103.9 m34.5 m215.1 m167.4 m138.1 m132.2 m89.4 m119.9 m95.8 m75.8 m

Accounts Receivable

4.5 m406 k363 k591 k

Current Assets

155 m128.9 m166.6 m192 m350.1 m333 m310.1 m484.6 m420 m353.9 m258.4 m236.7 m

PP&E

14 m14.3 m15.1 m17.5 m24 m26.1 m29.4 m36.6 m39.7 m41 m39.4 m38.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(52 m)(82.9 m)(156.9 m)(280 m)

Depreciation and Amortization

2.6 m4.4 m6 m8.5 m

Accounts Payable

4.2 m14 m9.1 m(4.8 m)

Cash From Operating Activities

(45.4 m)(87.1 m)60.8 m(255.5 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(37.9 m)(13.8 m)(31.7 m)(51.4 m)(24.4 m)(45 m)(78.1 m)(77.3 m)(156.6 m)(222.9 m)(43.9 m)(88.3 m)

Depreciation and Amortization

1.6 m980 k2 m3 m1.3 m2.8 m4.3 m2 m4.1 m6.3 m2.1 m4.2 m

Accounts Payable

623 k(4 m)(1.3 m)(164 k)(7.6 m)(8.3 m)(7.7 m)1.5 m9 m6.4 m(4.9 m)(105 k)

Cash From Operating Activities

(33.1 m)(20.4 m)(31.4 m)(47.2 m)(30.5 m)(42.8 m)(71.3 m)(69.8 m)(131.9 m)(194.2 m)(38.6 m)(69.4 m)
USDY, 2017

EV/EBIT

-22.5 x

EV/CFO

-13.5 x

EV/FCF

-13 x
Show all financial metrics

Novavax Operating Metrics

FY, 2016

Patents (US)

250

Phase I Trials

2

Phase II Trials

1

Phase III Trials

1
Show all operating metrics
Report incorrect company information

Novavax News and Updates

Merck's Ebola vaccine candidate could see early action against new Congo outbreak

​​​​​​​Merck & Co. and other biopharma players hustled to develop Ebola vaccines amid a devastating West Africa epidemic that started in 2014. Now, before Merck’s shot wins an official license, it could be used to combat a new outbreak in Congo.
Report incorrect company information